Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
XRTX
$0.409
$
XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is based in Vancouver, Canada.
Next Earnings
2026-02-25
Beta
0.15
Average Volume
Market Cap
Last Dividend
CIK
0001729214
ISIN
CA98420Q3061
CUSIP
98420Q207
CEO
Allen Warren Davidoff
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
2
IPO Date
2021-09-23
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| XORTX Announces Pioneering Research on Genome-Wide Pathogenic Pathways in Gout and Provides a Corporate Update | CALGARY, Alberta, Dec. 31, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, highlights recent peer-reviewed, independent, published research reports that expand current knowledge that genetic factors are linked to the over-expression of xanthine oxidase ("XO"), high chronic uric acid concentrations in the blood and gout. | Globe News Wire | 2025-12-31 18:15:00 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| EFFECT | 2026-02-17 | 2026-02-18 | View Filing |
| F-1/A | 2026-02-13 | 2026-02-12 | View Filing |
| 6-K | 2026-02-05 | 2026-02-04 | View Filing |
| 6-K | 2026-01-02 | 2026-01-02 | View Filing |
| 6-K | 2025-11-17 | 2025-11-17 | View Filing |
| 6-K | 2025-10-31 | 2025-10-31 | View Filing |
| 6-K | 2025-10-29 | 2025-10-29 | View Filing |
| SC 13G | 2025-10-27 | 2025-10-27 | View Filing |
| 6-K | 2025-10-23 | 2025-10-22 | View Filing |
| 424B5 | 2025-10-23 | 2025-10-22 | View Filing |
| 6-K | 2025-10-21 | 2025-10-21 | View Filing |
| 6-K | 2025-10-21 | 2025-10-21 | View Filing |
| 6-K | 2025-10-21 | 2025-10-20 | View Filing |
| 6-K | 2025-10-17 | 2025-10-17 | View Filing |
| 6-K | 2025-10-17 | 2025-10-17 | View Filing |
| F-1 | 2025-09-25 | 2025-09-25 | View Filing |
| 6-K | 2025-09-04 | 2025-09-04 | View Filing |
| 6-K | 2025-09-03 | 2025-09-03 | View Filing |
| 6-K | 2025-08-15 | 2025-08-15 | View Filing |
| 6-K | 2025-08-07 | 2025-08-07 | View Filing |
| 6-K | 2025-06-26 | 2025-06-26 | View Filing |
| 6-K | 2025-05-19 | 2025-05-19 | View Filing |
| 6-K | 2025-05-16 | 2025-05-16 | View Filing |
| SC 13G/A | 2025-05-15 | 2025-05-15 | View Filing |
| 20-F | 2025-05-12 | 2025-05-09 | View Filing |
| NT 20-F | 2025-05-01 | 2025-05-01 | View Filing |
| 6-K | 2025-04-30 | 2025-04-30 | View Filing |
| 6-K | 2025-04-28 | 2025-04-28 | View Filing |
| 6-K | 2025-04-18 | 2025-04-17 | View Filing |
| 6-K | 2025-04-01 | 2025-04-01 | View Filing |
| 6-K | 2025-03-26 | 2025-03-26 | View Filing |
| 6-K | 2025-03-19 | 2025-03-19 | View Filing |
| 6-K | 2025-02-24 | 2025-02-24 | View Filing |
| SC 13G | 2025-02-14 | 2025-02-14 | View Filing |
| 6-K | 2025-01-29 | 2025-01-29 | View Filing |
| 6-K | 2025-01-22 | 2025-01-22 | View Filing |
| 6-K | 2025-01-21 | 2025-01-21 | View Filing |
| 6-K | 2025-01-06 | 2025-01-06 | View Filing |
| 6-K | 2024-12-19 | 2024-12-19 | View Filing |
| 424B5 | 2024-12-13 | 2024-12-13 | View Filing |
| 6-K | 2024-12-12 | 2024-12-12 | View Filing |
| EFFECT | 2024-11-26 | 2024-11-26 | View Filing |
| 424B3 | 2024-11-22 | 2024-11-22 | View Filing |
| 424B3 | 2024-11-22 | 2024-11-22 | View Filing |
| F-1 | 2024-11-15 | 2024-11-15 | View Filing |
| 6-K | 2024-11-15 | 2024-11-15 | View Filing |
| D | 2024-10-31 | 2024-10-31 | View Filing |
| 6-K | 2024-10-24 | 2024-10-24 | View Filing |
| 6-K | 2024-10-18 | 2024-10-18 | View Filing |
| 6-K | 2024-10-18 | 2024-10-18 | View Filing |
| 6-K | 2024-10-18 | 2024-10-18 | View Filing |
| 424B5 | 2024-10-18 | 2024-10-18 | View Filing |
| 6-K | 2024-10-17 | 2024-10-17 | View Filing |
| 424B5 | 2024-10-17 | 2024-10-17 | View Filing |
| 6-K | 2024-10-09 | 2024-10-09 | View Filing |
| 424B3 | 2024-09-24 | 2024-09-24 | View Filing |
| 424B3 | 2024-09-24 | 2024-09-24 | View Filing |
| 424B3 | 2024-09-24 | 2024-09-24 | View Filing |
| 424B3 | 2024-09-24 | 2024-09-24 | View Filing |
| 424B3 | 2024-09-24 | 2024-09-24 | View Filing |
| 424B3 | 2024-09-24 | 2024-09-24 | View Filing |
| 6-K | 2024-09-13 | 2024-09-13 | View Filing |
| 6-K | 2024-09-13 | 2024-09-13 | View Filing |
| 6-K | 2024-09-13 | 2024-09-13 | View Filing |
| 6-K/A | 2024-09-13 | 2024-09-12 | View Filing |
| 6-K/A | 2024-09-13 | 2024-09-12 | View Filing |
| 6-K | 2024-09-06 | 2024-09-06 | View Filing |
| 6-K | 2024-09-04 | 2024-09-03 | View Filing |
| 6-K | 2024-08-29 | 2024-08-29 | View Filing |
| 6-K | 2024-08-23 | 2024-08-23 | View Filing |
| 6-K | 2024-08-22 | 2024-08-22 | View Filing |
| 6-K | 2024-08-20 | 2024-08-20 | View Filing |
| 6-K | 2024-08-15 | 2024-08-14 | View Filing |
| 424B3 | 2024-07-12 | 2024-07-12 | View Filing |
| 424B3 | 2024-07-12 | 2024-07-12 | View Filing |
| 6-K | 2024-07-01 | 2024-07-01 | View Filing |
| 424B3 | 2024-06-13 | 2024-06-13 | View Filing |
| 424B3 | 2024-06-13 | 2024-06-13 | View Filing |
| 424B3 | 2024-06-13 | 2024-06-13 | View Filing |
| 424B3 | 2024-06-13 | 2024-06-13 | View Filing |
| 424B3 | 2024-06-13 | 2024-06-13 | View Filing |
| 424B3 | 2024-06-13 | 2024-06-13 | View Filing |
| 424B3 | 2024-06-13 | 2024-06-13 | View Filing |
| 424B3 | 2024-06-13 | 2024-06-13 | View Filing |
| 424B3 | 2024-06-13 | 2024-06-13 | View Filing |
| 424B3 | 2024-06-13 | 2024-06-13 | View Filing |
| 424B3 | 2024-06-13 | 2024-06-13 | View Filing |
| 424B3 | 2024-06-13 | 2024-06-13 | View Filing |
| 6-K | 2024-06-12 | 2024-06-12 | View Filing |
| 6-K | 2024-06-04 | 2024-06-04 | View Filing |
| 6-K | 2024-05-20 | 2024-05-17 | View Filing |
| 6-K | 2024-05-17 | 2024-05-16 | View Filing |
| 20-F | 2024-05-10 | 2024-05-10 | View Filing |
| NT 20-F | 2024-05-01 | 2024-05-01 | View Filing |
| 6-K | 2024-04-30 | 2024-04-30 | View Filing |
| 6-K | 2024-04-22 | 2024-04-22 | View Filing |
| 6-K | 2024-04-08 | 2024-04-08 | View Filing |
| 6-K | 2024-04-08 | 2024-04-08 | View Filing |
| 6-K | 2024-04-04 | 2024-04-03 | View Filing |
| 6-K | 2024-03-27 | 2024-03-27 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Adaptive Wave | 6.23% | 0.97 | 4 | 0.32 | 0.26 | 20.8 |
| Quantum Inspired Strategy | 3.25% | 1 | 21 | 0.18 | 0.18 | 17.81 |
| Super Trend Strategy | 0.00% | 1 | 39 | 0 | 0 | 14.57 |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxxx |
| xxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxx | xx | xxxxx | xxxxx | xxxx |
| xxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | x |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxx | xxxxxxxx% | x | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |